Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Quick Links
Director's Corner
Dictionary of Cancer Terms
NCI Drug Dictionary
Funding Opportunities
NCI Publications
Advisory Boards and Groups
Science Serving People
Español
Questions about cancer?
1-800-4-CANCER
LiveHelp® online chat
NCI Highlights
Virtual and Standard Colonoscopy Both Accurate
Denosumab May Help Prevent Bone Loss
Past Highlights
Results:
1 -10 of 39
Show
10
25
50
100
200
results per page
View Search Criteria
|
Help With Results
Sort By:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Version:
Health Professional
Patient
Format:
Short
------
Short
Medium
Long
Custom
1.
AIDA2000 - Risk-Adapted Therapy for Patients With Acute Promyelocytic Leukemia
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase IV
Treatment
Active
16 and over
Other
MK1-192
NCT00180128
2.
Therapy of Acute Myeloid Leukemia in Patients Over the Age of 60 : DA Versus Mitoxantrone With Intermittent AraC
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase IV
Treatment
Active
60 and over
Other
AML_GT60_DD
NCT00180167
3.
Treatment of Newly Diagnosed Patients With Acute Promyelocytic Leukemia (PETHEMA LPA 2005)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase IV
Treatment
Active
0 to 75
Other
LPA 2005
NCT00408278
4.
Treatment of Relapsed Promyelocytic Leukemia With Arsenic Trioxide (ATO)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase IV
Treatment
Active
18 and over
Other
LAP-R2007
NCT00504764
5.
LAL-Ph-2000: Treatment of Acute Lymphoblastic Leukemia Chromosome Philadelphia Positive
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase IV
Treatment
Active
65 and under
Other
LAL-Ph-2000
NCT00526305
6.
Treatment Protocol for Relapsed Acute Promyelocytic Leukemia (APL) With Arsenic
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase IV
Treatment
Active
18 and over
Other
30052004
NCT00196768
Last Modified:
4/28/2008
 
First Published:
5/21/2007
7.
Phase II/III Randomized Study of Therapy Optimization Comprising Induction, Consolidation, and Intensification Regimens Followed By CNS Radiotherapy and Maintenance Therapy Comprising Thioguanine and Cytarabine in Pediatric Patients With Standard-Risk or High-Risk Acute Myeloid Leukemia
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III, Phase II
Treatment
Active
18 and under
Other
UCHM-AML-BFM-2004
UCHM-BfArM 4022064, NCT00111345, UCHM-DKH 50-2728, EU-20723, AML-BFM 2004
Last Modified:
12/5/2007
 
First Published:
4/1/1999
8.
Phase III Randomized Study of Dexamethasone Versus Prednisolone During Induction Therapy and Prolonged Versus Conventional Duration Asparaginase During Consolidation and Late Intensification Therapy in Children With Acute Lymphoblastic Leukemia or Lymphoblastic Non-Hodgkin's Lymphoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Active
Under 18
Other
EORTC-58951
NCT00003728
Last Modified:
8/21/2008
 
First Published:
12/22/2004
9.
Phase III Randomized Study of Pixantrone Versus Other Chemotherapeutic Agents as Third-Line Single Agent Therapy in Patients With Relapsed Aggressive Non-Hodgkin's Lymphoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Active
18 and over
NCI, Pharmaceutical / Industry
UCLA-0406049-01
CTI-PIX301, NCT00101049
Last Modified:
10/17/2008
 
First Published:
8/24/2006
10.
Phase III Randomized Study of Conventional Combination Chemotherapy With Versus Without Gemtuzumab Ozogamicin in Young Patients With Newly Diagnosed Acute Myeloid Leukemia
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Active
Under 30
NCI
COG-AAML0531
AAML0531, NCT00372593
Select All on One Page
1
2
3
4
Next >
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute